Home › Funds › Trails Edge Capital Partners, LP › AVTX
Trails Edge Capital Partners, LP position in AVTX
AVALO THERAPEUTICS INC · Health Care
Trails Edge Capital Partners, LP reported holding 1,500,000 shares of AVTX (AVALO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$23.0M, representing 3.30% of its reported portfolio and ranking #14 among its reported holdings. Trails Edge Capital Partners, LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's AVTX position evolved
Trails Edge Capital Partners, LP first disclosed a stake in AVTX in Q2 2026 at 891,881 shares (US$16.5M). The position peaked in Q3 2026 at 1,500,000 shares, worth US$23.0M. Across 2 filings, Trails Edge Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,500,000 shares valued at US$23.0M — an increase of 608,119 shares quarter over quarter.. Notable position changes include a 68% increase in Q3 2026 (shares fell 49% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 891.88K | $16.48M | New |
| Q3 2026 | 1.50M | $23.00M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in AVTX — the largest reported positions include FARALLON CAPITAL MANAGEMENT, L.L.C. (US$60.9M), Caligan Partners LP (US$58.5M), Deep Track Capital, LP (US$55.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- FARALLON CAPITAL MANAGEMENT, L.L.C. 3.97M sh · $60.92M · Q3 2026
- Caligan Partners LP 3.16M sh · $58.47M · Q2 2026
- Deep Track Capital, LP 3.61M sh · $55.34M · Q3 2026
- Affinity Asset Advisors, LLC 3.24M sh · $49.74M · Q3 2026
- TCG Crossover Management, LLC 3.02M sh · $46.25M · Q3 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- BVF INC/IL 2.08M sh · $38.36M · Q2 2026
- Avoro Capital Advisors LLC 2.38M sh · $36.45M · Q3 2026
- Nantahala Capital Management, LLC 2.14M sh · $32.84M · Q3 2026
- Soleus Capital Management, L.P. 1.65M sh · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M sh · $30.11M · Q2 2026
- Logos Global Management LP 1.50M sh · $23.00M · Q3 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held AVTX?
Trails Edge Capital Partners, LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Trails Edge Capital Partners, LP's current position in AVTX?
As of Q3 2026, Trails Edge Capital Partners, LP holds 1.50M shares of AVTX (AVALO THERAPEUTICS INC), valued at $23.00M, representing 3.30% of its reported portfolio and ranking #14.
Has Trails Edge Capital Partners, LP been buying or selling AVTX?
In the latest 13F filing (Q3 2026), Trails Edge Capital Partners, LP increased its position in AVTX. The position peaked in Q3 2026 at 1.50M shares.
Which other funds hold AVTX?
Other major institutional holders of AVTX include FARALLON CAPITAL MANAGEMENT, L.L.C., Caligan Partners LP, Deep Track Capital, LP, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.